The short version
- The 2003 Nature paper that launched resveratrol reported a 70% lifespan extension in budding yeast, and every subsequent claim about human longevity was an inference chain hanging off that result.
- The influential 2006 mouse study tested middle-aged mice on a high-calorie diet and showed resveratrol shifting them back toward the control condition, which is a different claim from extending healthy lifespan in mammals.
- A 2010 study using native substrates found resveratrol did not activate SIRT1 unless the test peptide carried an attached fluorophore that the compound bound directly, indicating the original activation may have been an artefact of the assay.
- Re-running sirtuin overexpression experiments with standardised genetic backgrounds and proper controls in 2011 abolished the apparent lifespan effects in both C. elegans and Drosophila.
- In 783 older Italian adults followed for nine years, mortality across quartiles of urinary resveratrol metabolites was 34.4%, 31.6%, 33.5% and 37.4% (p = 0.67), with no association with inflammation, cardiovascular disease or cancer.
In September 2003, Nature published a paper reporting three classes of small molecules that activate sirtuins. The most potent of them was resveratrol, a polyphenol found in red wine. In the paper, it lowered the Michaelis constant of SIRT1 for both its substrate and NAD+, increased cell survival through SIRT1-dependent deacetylation of p53, and — the number that travelled — mimicked calorie restriction in yeast, increasing DNA stability and extending lifespan by 70%.
Seventy per cent, in budding yeast. Everything the world subsequently believed about resveratrol was an inference chain hanging off that result. Follow where the chain broke and you have a method you can apply to the next longevity molecule, including anything we sell you.
Step one: the mouse paper that made it a category
In 2006, again in Nature, Baur and colleagues reported that resveratrol shifted the physiology of middle-aged mice on a high-calorie diet toward that of mice on a standard diet, and significantly increased their survival. Insulin sensitivity up, IGF-1 down, AMPK and PGC-1-alpha activity up, more mitochondria, better motor function. A pathway analysis found resveratrol opposing the effects of the high-calorie diet in 144 of 153 significantly altered pathways.
It is a genuinely impressive paper. Read the population it studied, though, because this is where the retail story quietly changed. These were middle-aged mice being harmed by their diet, and the drug moved them back toward the control condition. "Partly offsets the damage of a bad diet in mice" is a different claim from "extends healthy lifespan in mammals" — and it is the second one that ended up on the bottle.
Step two: the mechanism did not survive a better assay
In 2010, a team at Pfizer re-ran the biochemistry using native substrates rather than the ones in the original assays: a p53-derived peptide with no fluorophore attached, plus the purified full-length proteins p53 and acetyl-CoA synthetase 1.
Resveratrol did not appear to activate SIRT1 under those conditions. Neither did the pharmaceutical compounds built on the same premise. All of them did activate SIRT1 when the peptide substrate carried a covalently attached fluorophore — and NMR, surface plasmon resonance and calorimetry showed the compounds binding directly to those fluorophore-containing peptides. In other words, the apparent activation looked like an interaction with the measurement tag rather than with the biology. The same paper reported that the lead compound neither lowered plasma glucose nor improved mitochondrial capacity in mice on a high-fat diet, and that all of them had multiple off-target activities.
This is the single most transferable lesson in the episode. The measurement can be the finding. A result that only appears with one assay is a result about that assay until someone shows otherwise.
Step three: the underlying biology got re-run too
In 2011 a large collaboration re-examined whether overexpressing sirtuins extends life in worms and flies at all. Standardising the genetic background and using appropriate transgenic controls abolished the apparent effect in both species. In C. elegans, outcrossing showed longevity travelling with a second-site mutation affecting sensory neurons rather than with the sirtuin overexpression itself. In Drosophila, a strain that looked long-lived against wild-type was not long-lived against the correct controls. Dietary restriction extended fly lifespan whether or not the sirtuin was there.
Note how the authors phrased their conclusion: this does not rule out a role for sirtuins in lifespan, but it casts doubt on the robustness of the previously reported effects. That careful, bounded sentence is what a real scientific correction sounds like. It is nothing like the confidence of the marketing that had already been built on top.
Step four: what it did in actual people
The closest thing to a real-world test came from the InCHIANTI study — 783 community-dwelling men and women aged 65 and over in two villages in the Chianti region, with 24-hour urinary resveratrol metabolites measured and nine years of follow-up. Two hundred and sixty-eight of them died.
Across quartiles of resveratrol metabolites from lowest to highest, the proportion who died was 34.4%, 31.6%, 33.5% and 37.4%. The p-value was 0.67. Lowest versus highest quartile gave a hazard ratio of 0.80 with a confidence interval from 0.54 to 1.17 — which is to say, nothing. There was no association with CRP, IL-6, IL-1-beta, TNF, or with cardiovascular disease or cancer.
Be precise about what that does and does not test. It measured resveratrol from diet, in one Italian cohort, not a 500mg capsule in a randomised trial. But it is a direct test of the story that made the molecule famous — that resveratrol is why red-wine drinkers seem to do well — and the answer came back flat.
The four questions this teaches you
Take these to the next longevity claim you meet, ours included.
- What species, and in what condition? Yeast, and mice being harmed by their diet, are not a healthy 45-year-old.
- Is the outcome the thing you care about, or a marker standing in for it? Deacetylation activity is not extra years.
- Has anyone tried to break the mechanism, and what happened? Someone always should. If nobody has, the finding is young.
- What did it do in humans who were not ill, at a dose a person takes? This is where most longevity stories run out of road.
Applied to us
NAD precursors are the current instalment of this exact story, and we sell them. We have written up the human evidence for NAD and NMN separately, and the short version is that the marker reliably moves while the outcomes mostly have not — which is step two of the resveratrol arc, not step four.
That is not an argument against buying them. It is an argument for knowing which step you are buying at, and for holding us to the four questions above every time. If we ever answer them badly, we have earned whatever you conclude.
Good questions
Does resveratrol actually extend lifespan in humans?
There is no evidence that it does. The lifespan results came from yeast and from mice on a high-calorie diet, the proposed mechanism did not survive better assays, and the one large human cohort study measuring dietary resveratrol found no association with mortality over nine years.
Should I stop taking resveratrol?
That is your call, but nothing in this record supports buying it for longevity. If you take it for another reason, or simply like the routine, the safety picture in human trials has not been the problem — the efficacy claim has. We would put the money into fitness and strength work instead.
Was the original sirtuin research fraudulent?
That is not what the record shows, and we are not going to imply it. What happened is more ordinary and more instructive: an assay artefact, an over-read of animal data, and genetic backgrounds that were not properly controlled. Three technical problems, corrected in public by other scientists, over about eight years.
Is NMN or NAD going the same way as resveratrol?
Too early to say, and we sell both, so treat this as a disclosure. NAD precursors reliably raise the blood marker, which is genuinely more than resveratrol ever established. Whether that produces an outcome you would notice is unresolved. We have written up the human trials separately rather than summarising them favourably here.
How can I tell if a longevity claim is worth anything?
Ask four things: what species and in what condition, whether the outcome is the thing you care about or a stand-in marker, whether anyone has tried to break the mechanism, and what it did in humans who were not ill at a dose people actually take. Most claims fail on the fourth.
Does red wine still count as healthy because of resveratrol?
The resveratrol part of that story did not hold up. The InCHIANTI cohort measured actual dietary resveratrol in older adults and found no relationship with mortality, inflammation, heart disease or cancer. Whatever you conclude about wine, resveratrol is not the reason, and the doses in a glass are tiny regardless.
Sources
- Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003. View study
- Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006. View study
- Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem, 2010. View study
- Burnett C, Valentini S, Cabreiro F, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature, 2011. View study
- Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med, 2014. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
